HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

J. Biol. Chem., Vol. 281, Issue 17, 12069-12080, April 28, 2006

This Article Full Text Full Text (PDF) Supplemental Data All Versions of this Article: 281/17/12069    most recent M511621200v1 Submit a Letter to Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hsu, T. Articles by Dammai, V. Search for Related Content PubMed PubMed Citation Articles by Hsu, T. Articles by Dammai, V. Social Bookmarking                      What's this?

Endocytic Function of von Hippel-Lindau Tumor Suppressor Protein Regulates Surface Localization of Fibroblast Growth Factor Receptor 1 and Cell Motility^*

From the Department of Pathology and Laboratory Medicine and Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina 29425

The tumor suppressor VHL (von Hippel-Lindau protein) serves as a negative regulator of hypoxia-inducible factor- subunits. However, accumulated evidence indicates that VHL may play additional roles in other cellular functions. We report here a novel hypoxia-inducible factor-independent function of VHL in cell motility control via regulation of fibroblast growth factor receptor 1 (FGFR1) endocytosis. In VHL null tumor cells or VHL knock-down cells, FGFR1 internalization is defective, leading to surface accumulation and abnormal activation of FGFR1. The enhanced FGFR1 activity directly correlates with increased cell migration. VHL disease mutants, in two of the mutation hot spots favoring development of renal cell carcinoma, failed to rescue the above phenotype. Interestingly, surface accumulation of the chemotactic receptor appears to be selective in VHL mutant cells, since other surface proteins such as epidermal growth factor receptor, platelet-derived growth factor receptor, IGFR1, and c-Met are not affected. We demonstrate that 1) FGFR1 endocytosis is defective in the VHL mutant and is rescued by reexpression of wild-type VHL, 2) VHL is recruited to FGFR1-containing, but not EGFR-containing, endosomal vesicles, 3) VHL exhibits a functional relationship with Rab5a and dynamin 2 in FGFR1 internalization, and 4) the endocytic function of VHL is mediated through the metastasis suppressor Nm23, a protein known to regulate dynamin-dependent endocytosis.

Received for publication, October 26, 2005 , and in revised form, February 16, 2006.

^* This work was initially supported by the VHL Family Alliance (to T. H.) and subsequently by National Institutes of Health Grants PO1CA78582 and RO1CA109860 (to T. H.) and a Medical University of South Carolina/Department of Defense phase VII (Geocenters) grant (to V. D.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

The on-line version of this article (available at http://www.jbc.org) contains supplemental Figs. S1 and S2.

¹ To whom correspondence may be addressed: Dept. of Pathology and Laboratory Medicine and Hollings Cancer Center, Medical University of South Carolina, 86 Jonathan Lucas St., HCC330, Charleston, SC 29425. Tel.: 843-792-0638; Fax: 843-792-5002; E-mail: hsut{at}musc.edu.

² To whom correspondence may be addressed: Dept. of Pathology and Laboratory Medicine and Hollings Cancer Center, Medical University of South Carolina, 86 Jonathan Lucas St., HCC321, Charleston, SC 29425. Tel.: 843-792-1677; Fax: 843-792-5002; E-mail: dammaiv{at}musc.edu.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				M. Feijoo-Cuaresma, F. Mendez, A. Maqueda, M. A. Esteban, S. Naranjo-Suarez, M. C. Castellanos, M. H. del Cerro, S. N. Vazquez, A. Garcia-Pardo, M. O. Landazuri, et al. Inadequate Activation of the GTPase RhoA Contributes to the Lack of Fibronectin Matrix Assembly in von Hippel-Lindau Protein-defective Renal Cancer Cells J. Biol. Chem., September 5, 2008; 283(36): 24982 - 24990. [Abstract] [Full Text] [PDF]

				S. Mahajan, V. Dammai, T. Hsu, and A.S. Kraft Hypoxia-inducible factor-2{alpha} regulates the expression of TRAIL receptor DR5 in renal cancer cells Carcinogenesis, September 1, 2008; 29(9): 1734 - 1741. [Abstract] [Full Text] [PDF]

				K. J. Champion, M. Guinea, V. Dammai, and T. Hsu Endothelial Function of von Hippel-Lindau Tumor Suppressor Gene: Control of Fibroblast Growth Factor Receptor Signaling Cancer Res., June 15, 2008; 68(12): 4649 - 4657. [Abstract] [Full Text] [PDF]

				M. R. Chintalapudi, M. Markiewicz, N. Kose, V. Dammai, K. J. Champion, R. S. Hoda, M. Trojanowska, and T. Hsu Cyr61/CCN1 and CTGF/CCN2 mediate the proangiogenic activity of VHL-mutant renal carcinoma cells Carcinogenesis, April 1, 2008; 29(4): 696 - 703. [Abstract] [Full Text] [PDF]

				G. Nallamothu, J. A. Woolworth, V. Dammai, and T. Hsu awd, the Homolog of Metastasis Suppressor Gene Nm23, Regulates Drosophila Epithelial Cell Invasion Mol. Cell. Biol., March 15, 2008; 28(6): 1964 - 1973. [Abstract] [Full Text] [PDF]

				K. L. Wu, H. Miao, and S. Khan JAK kinases promote invasiveness in VHL-mediated renal cell carcinoma by a suppressor of cytokine signaling-regulated, HIF-independent mechanism Am J Physiol Renal Physiol, December 1, 2007; 293(6): F1836 - F1846. [Abstract] [Full Text] [PDF]

				J. A. Garcia HIFing the Brakes: Therapeutic Opportunities for Treatment of Human Malignancies Sci. Signal., May 30, 2006; 2006(337): pe25 - pe25. [Abstract] [Full Text] [PDF]